{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}],"units":"Participants"}],"description":"Number of patients with best response using RECIST 1.1 criteria of partial response (at least a 30% decrease in the sum of the diameters of target lesions) or complete response (disappearance of all target and non-target lesions and any pathological lymph nodes must have reduction in short axis to \\<10 mm).","groups":[{"description":"35 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course (Pre-amendment #1)","id":"OG000","title":"Part A: Dose Level 1"},{"description":"35 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course (Amendment 1)","id":"OG001","title":"Part A: Dose Level 1 (DL 1)"},{"description":"20 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course","id":"OG002","title":"Part A: Dose Level -1 (DL -1)"},{"description":"45 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG003","title":"Part A: Weekly Dose Level 1 (WDL 1)"},{"description":"35 mg/m2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG004","title":"Part A: Weekly Dose Level -1 (WDL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG005","title":"Part B: Weekly Dose Level -1 (WDL -1)"},{"description":"20 mg/m2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course","id":"OG006","title":"Part PK: Dose Level -1 (DL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG007","title":"Part PK: Weekly Dose Level -1 (WDL -1)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Responsive patients","reportingStatus":"POSTED","timeFrame":"Up to 6 years 11 months","title":"Antitumor Effect of Selinexor","type":"SECONDARY","unitOfMeasure":"Participants"}